# Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

> **NCT03208465** · PHASE4 · COMPLETED · sponsor: **CHEOL WHAN LEE, M.D., Ph.D** · enrollment: 100 (actual)

## Conditions studied

- Diabetes Mellitus
- Coronary Disease

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT03208465
- **Lead sponsor:** CHEOL WHAN LEE, M.D., Ph.D
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-07
- **Primary completion:** 2019-08-01
- **Final completion:** 2019-08-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03208465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03208465, "Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03208465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*